Navigation Links
A New Way to Get Chemo to Pancreatic Tumors
Date:5/21/2009

Technique that doubles life span in mice may hold hope for people,,

THURSDAY, May 21 (HealthDay News) -- Researchers are reporting that they've discovered a way to boost chemotherapy and slightly extend the lives of mice with pancreatic cancer, potentially paving the way for more effective treatments in people.

There's no guarantee that the strategy would work in humans. And, even if it did, the researchers don't expect that it would add many months to people's lives.

Still, scientists are "cautiously optimistic," said Dr. David Tuveson, lead author of a study released online May 21 in Science and a researcher at the Cambridge Research Institute in England.

Questions about such factors as cost, though, remain to be answered, Tuveson acknowledged.

Pancreatic tumors are among the most difficult types of cancer to treat. Roughly 5 percent of people diagnosed with the more common form of the disease are expected to survive five years from diagnosis, according to the American Cancer Society.

"It usually gets diagnosed when it is already very advanced because the symptoms don't usually begin until the cancer is advanced," said Dr. Allyson J. Ocean, assistant professor of medicine at the Jay Monahan Center for Gastrointestinal Health at New York-Presbyterian Hospital/Weill Cornell Medical College in New York City. Pancreatic cancer is resistant to chemotherapy and radiation, she added, and tumors are often aggressive and likely to spread.

Doctors think the disease is especially difficult to treat with chemotherapy because the tumors don't have many blood vessels to carry drugs to where they need to be to kill cancer cells.

In the study, researchers genetically engineered mice to develop a form of pancreatic cancer. The scientists then gave them a chemotherapy drug called gemcitabine (Gemzar) and another compound they hoped would boost blood flow in the tumors.

The survival time of the mice, on average, doubled from 11 to 25 days when they were treated with the chemotherapy drug and the compound, which is known only by a code. That may not seem like much, Tuveson said, but in people, "a doubling of overall survival from six to 12 months would be meaningful."

Dr. Aaron Sasson, chief of gastrointestinal surgical oncology at the University of Nebraska Medical Center, pointed out that some previous pancreatic treatments have worked well in mice but failed in humans. But the researchers behind the new study may have discovered a "trick" to a more effective treatment, he said.

Nonetheless, it would be quite some time before the treatment could reach doctors' offices, he said. Cost could be an issue, too: Some chemotherapy drugs, he said, cost thousands of dollars a month.

In the big picture, the treatment might extend life span by just a few months, he said. But the strategy could help make tumors more vulnerable to other types of chemotherapy drugs.

"It's possible that other chemotherapy drugs that failed before could become effective," he said.

More information

The American Cancer Society has more on pancreatic cancer.



SOURCES: David Tuveson, M.D., researcher, Cambridge Research Institute, Cambridge, England; Aaron Sasson, M.D., associate professor, surgery, and chief, gastrointestinal surgical oncology, University of Nebraska Medical Center, Omaha; Allyson J. Ocean, M.D., assistant professor, medicine, Jay Monahan Center for Gastrointestinal Health, New York-Presbyterian Hospital/Weill Cornell Medical College, New York City; May 21, 2009, Science


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
2. Ginger Eases Nausea From Chemo
3. Study shows chemotherapy improves survival among older breast cancer patients
4. Chemotherapy Superior to New Drug for Early Breast Cancer
5. Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa
6. 3-Drug Combo Reduces Nausea After Chemo
7. Delivering Chemo Directly Into Brain Tumors Shows Promise
8. Chemo Combo Shows Promise Against Ovarian Cancer
9. Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers
10. Radiation-Chemo Combo Boosts Lung Cancer Outcomes
11. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A New Way to Get Chemo to Pancreatic Tumors
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... and print media enterprise focused entirely on patients with cancer, today announced that ... was chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... outsourced billing and coding services, and Deyta Analytics, recently announced the recipients of ... highest level of quality as measured from the caregiver’s point of view. The ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Pro3rd Grunge ... Utilize Pixel Film Studios’ lower thirds to introduce people, characters, and locations without having ... include boxes, lines, accents, textures and many more design components. Simply select a preset ...
(Date:4/28/2016)... ... April 29, 2016 , ... Monthly subscription boxes are all the rage, and ... recently reviewed the ZEN BOX , the aromatherapy subscription box. , ZEN BOX delivers ... lavender or frankincense) and one Zen Blend (like immune boost, sublime sleep or de-stress ...
(Date:4/28/2016)... ... 28, 2016 , ... La Sirena Foods provides premium canned seafood, specifically, Tuna, ... looking to grow their market share in the USA. , "We are happy to ... Sirena Foods and indirectly with Otis McAllister , a leading global food ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
(Date:4/27/2016)... NORWALK, Conn. , April 27, 2016 /PRNewswire/ ... availability of its digital health technology platform, which ... services and programs into scalable digital products, Zillion ... mobile engagement and empower consumers to take control ... features face-to-face live video conferencing – including one-to-one, ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: